Impaired Glucose Tolerance, Prediabetes
Conditions
Keywords
impaired glucose tolerance, obesity, adolescents
Brief summary
The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.
Detailed description
The purpose of this research is to evaluate if having blood sugar information from a continuous glucose monitor (CGM) during activities of daily living provides additional benefit to lifestyle modifications in reducing the risk of developing diabetes and achieving a healthier weight. A CGM is a small device often worn on the back of the arm that uses a very small needle to insert a small sensor just under the skin in the fatty tissue. The CGM device transmits the blood sugar level to either a smartphone or a special receiver. The investigators expect patients will have an overall improvement in health by decreasing weight and therefore improving the way the child's insulin works in their body. This could result in decreased risk of obesity-related complications such as diabetes mellitus, cardiovascular disease, kidney disease, and loss of vision and/or limbs, among others.
Interventions
DEVICECGM
Dexcom G7 sensor, transmitter and supplies will be provided to family for use. Participants will wear G7 and have real-time glucose data throughout the study.
Sponsors
Nemours Children's Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Children 10 to \<18 years old (i.e., before their 18th birthday) 2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) or fasting glucose per American Diabetes Association criteria, 3. Overweight or obese (BMI ≥85th percentile for age/sex) 4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL
Exclusion criteria
1. Existing diagnosis of type 1 or type 2 diabetes 2. Prepubertal 3. Taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). Metformin allowed if stable dose. 4. Patients and/or families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin Sensitivity Score (ISS) | Baseline to 6 months | Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| QUICKI insulin sensitivity | Baseline to 3 months | Change in insulin sensitivity as measured by QUICKI |
| Insulin Sensitivity Score | Baseline to 3 months | Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance. |
| Glycemic levels | Baseline to 3 and 6 months | Change in characteristics of glycemic levels obtained from the CGM data. This will include: * mean, standard deviation of glucose levels * time in range (glucose between 70-140 mg/dL) * percent of time with hyperglycemia (\>140 mg/dL) * percent of time with hypoglycemia (\<70 mg/dL) |
| Mean, standard deviation of sensor glucose levels | Baseline to 3 and 6 months | Change in characteristics of glycemic levels obtained from the CGM data, including mean and standard deviation of sensor glucose levels (mg/dL). |
| Time in range of sensor glucose levels | Baseline to 3 and 6 months | Change in glycemic levels obtained from the CGM data: Percent of time in range (glucose between 70-140 mg/dL) |
| Percent of sensor glucose levels in hypoglycemic range | Baseline to 3 and 6 months | Change in glycemic levels obtained from the CGM data: Percent of time with hypoglycemia (\<70 mg/dL) |
| Percent of sensor glucose levels in hyperglycemic range | Baseline to 3 and 6 months | Change in glycemic levels obtained from the CGM data: Percent of time with hyperglycemia (\>140 mg/dL) |
| Physical activity questionnaires | 3 and 6 months | Questionnaires will be used to assess amount of time participants are active. Two questions regarding physical activity will be asked, with a scale set up as follows: 1. How many minutes of continuous physical activity per week were completed? Possible answers will be \<10, 11-20, 21-30, 31-60, 61-90, 91-120, or 121-150. 2. How many days per week of physical activity longer than 30 minutes? Possible answers will be 0, 1, 2, 3, 4, 5, 6, or 7. |
| Dietary compliance questionnaires | 3 and 6 months | Questionnaires will be used to assess particpants' compliance witih dietary changes. Four questions regarding their diet will be asked, with a scale set up as follows: 1. How many sugary drinks per week? Possible answers will be 0, 1-2, 3-5, or \>5. 2. How many unhealthy snacks per week? Possible answers will be 0, 1-2, 3-5, or \>5. 3. How many times junk food was consume in the past week? Possible answers will be 0, 1-2, 3-5, or \>5. 4. How often were the proper portion sizes followed (as per control plate)? Possible answers will be always, most days, occasionally, or never. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLarry A Fox, MD
Nemours Children's Health
Outcome results
None listed